Adaptive Biotech Q1 2025: Genentech Deal, Medicare Reimbursements
Ticker: ADPT · Form: 10-Q · Filed: May 1, 2025 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, collaboration, reimbursements
TL;DR
**Adaptive Biotech Q1 2025:** Genentech deal & Medicare reimbursements progressing. Fair value & debt metrics updated.
AI Summary
Adaptive Biotechnologies Corp. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing indicates ongoing activities related to its Genentech Collaboration Agreement and Medicare Reimbursements. Financial data points include fair value measurements for recurring items and corporate debt securities as of March 31, 2025.
Why It Matters
This filing provides insight into Adaptive Biotechnologies' financial health and operational progress, particularly concerning its key collaborations and revenue streams.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive biotechnology sector, with significant reliance on collaborations and reimbursement policies.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the financial snapshot date)
- 20250501 — Filing Date (Date the report was submitted to the SEC)
Key Players & Entities
- Adaptive Biotechnologies Corp. (company) — Filer of the 10-Q
- Genentech (company) — Mentioned in relation to a collaboration agreement
- Medicare (company) — Mentioned in relation to reimbursements
- 20250331 (date) — End of the reporting period
- 20250501 (date) — Filing date
FAQ
What is the current status of the Genentech Collaboration Agreement?
The filing references the Genentech Collaboration Agreement as of March 31, 2025, indicating it is an active and relevant part of the company's operations.
How are Medicare reimbursements impacting Adaptive Biotechnologies?
The filing notes Medicare Reimbursements for the period of January 1, 2025, to March 31, 2025, suggesting it is a material revenue or operational factor.
What are the key fair value measurements reported?
The report includes fair value measurements for recurring items and corporate debt securities as of March 31, 2025.
Are there any significant debt-related disclosures in this filing?
Yes, the filing includes information on corporate debt securities and their fair value measurements as of March 31, 2025.
What is the company's fiscal year end?
Adaptive Biotechnologies Corp.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Adaptive Biotechnologies Corp (ADPT).